Vera Bril
Co-Applicant
Professor of Neurology at University of Toronto | Neurologist and Director of the Neuromuscular Section at University Health Network and the University of Toronto
Senior Scientist at the Toronto General Research Institute
NMD4C Involvement: Pillar 2: Clinical Research, Pillar 3: Clinical Practice Research
Biography
Vera Bril is a Professor of Medicine (Neurology) at the University of Toronto, Director of the Neuromuscular Section, Division of Neurology, University of Toronto and University Health Network. She directs the Ellen & Martin Prossserman Centre for Neuromuscular Diseases at the University Health Network, and the Prosserman Family Neuromuscular Clinic and the Elisabeth Raab Neurofibromatosis Clinic at Toronto General Hospital. She has particular expertise in the diagnosis and management of patients with complex neuromuscular disorders. Her research interests have centered on the diagnosis and evidence-based treatment of myasthenia gravis, inflammatory polyneuropathies, and diabetic sensorimotor polyneuropathy leading to publication of more than 350 journal articles.
Recent Publications
Almasri, A, Bril, V, Katzberg, H. Quality of Life in Patients with Chronic Inflammatory Demyelinating Neuropathies Treated with Subcutaneous Immunoglobulin. Can J Neurol Sci. 2025. 1-7 PMID:40891262
Chou, M, Mendoza, M, Katzberg, H, Bril, V, Barnett-Tapia, C. A Cross-Sectional Study of Quality of Life and Body Image in Myasthenia Gravis Patients: A Novel Approach Using the Individualized Neuromuscular Quality of Life Questionnaire. Muscle Nerve. 2025. PMID:40842122
Kaminski, HJ, Antozzi, C, Habib, AA, Pascuzzi, RM, Sacconi, S, Utsugisawa, K et al.. Improvement in Patient-Reported Symptoms of Generalised Myasthenia Gravis With Rozanolixizumab in the Randomised Phase 3 MycarinG Study Using the MG Symptoms PRO. Eur J Neurol. 2025.32 (8)e70231 PMID:40755069
Menon, D, Bril, V, Barnett-Tapia, C. Author Response: Effect of Immunosuppression in Risk of Developing Generalized Symptoms in Ocular Myasthenia Gravis: A Retrospective Cohort Study. Neurology. 2025.105 (4)e210073 PMID:40680252
Bril, V, Gilhus, NE. Response to letter from zi yin Yao. J Neurol Sci. 2025.475 123566 PMID:40516173
Gonçalves, LI, Bril, V. Variability in Conduction Block Definitions Affects the Sensitivity of Diagnostic Criteria for Multifocal Motor Neuropathy. J Peripher Nerv Syst. 2025.30 (2)e70034 PMID:40511490
Fine, N, Ducharme, A, Matte, G, Mezei, M, Bril, V, Delgado, D et al.. Diagnosis and Management of Mixed Phenotype Hereditary Transthyretin Amyloidosis: A Case-Based, Canadian Perspective. CJC Open. 2025.7 (5)614-627 PMID:40433205
Matic, A, Bril, V. Rozanolixizumab for Myasthenia Gravis: a breakthrough treatment and future prospects. Immunotherapy. 2025.17 (5)309-316 PMID:40277145
Pasnoor, M, Anderson-Smits, C, Levine, T, Bril, V, Solano, JM, Rejdak, K et al.. The Results of ADVANCE-CIDP IVIG Trial: Intravenous Immunoglobulin 10% Therapy With GAMMAGARD LIQUID/Kiovig for Treatment of Relapse in Chronic Inflammatory Demyelinating Polyradiculoneuropathy. Eur J Neurol. 2025.32 (4)e70110 PMID:40247653
Alghabban, A, Corke, L, Katzberg, H, Bril, V, Barnett-Tapia, C, Mason, W et al.. Myasthenia Gravis in Patients Treated With Immune Checkpoint Inhibitors. JTO Clin Res Rep. 2025.6 (5)100772 PMID:40242666
See more on PubMed